StockNews.com Upgrades MediWound (NASDAQ:MDWD) to “Hold”

MediWound (NASDAQ:MDWD) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Friday.

Separately, HC Wainwright restated a “buy” rating and issued a $28.00 price target on shares of MediWound in a research report on Friday.

MediWound Trading Up 0.1 %

NASDAQ:MDWD traded up $0.02 during mid-day trading on Friday, hitting $15.97. 242,746 shares of the company’s stock were exchanged, compared to its average volume of 58,984. The company has a 50 day simple moving average of $13.83 and a 200-day simple moving average of $10.85. MediWound has a fifty-two week low of $7.10 and a fifty-two week high of $17.25. The firm has a market capitalization of $147.08 million, a P/E ratio of -9.07 and a beta of 0.94.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in MDWD. Renaissance Technologies LLC lifted its position in MediWound by 3.8% in the 2nd quarter. Renaissance Technologies LLC now owns 475,422 shares of the biopharmaceutical company’s stock valued at $875,000 after acquiring an additional 17,600 shares in the last quarter. Alyeska Investment Group L.P. bought a new position in MediWound in the 1st quarter valued at about $1,998,000. Yelin Lapidot Holdings Management Ltd. lifted its position in MediWound by 45.7% in the 4th quarter. Yelin Lapidot Holdings Management Ltd. now owns 125,493 shares of the biopharmaceutical company’s stock valued at $1,276,000 after acquiring an additional 39,348 shares in the last quarter. Wells Fargo & Company MN lifted its position in MediWound by 16.0% in the 2nd quarter. Wells Fargo & Company MN now owns 112,727 shares of the biopharmaceutical company’s stock valued at $1,202,000 after acquiring an additional 15,535 shares in the last quarter. Finally, Sphera Funds Management LTD. lifted its position in MediWound by 47.4% in the 1st quarter. Sphera Funds Management LTD. now owns 111,127 shares of the biopharmaceutical company’s stock valued at $1,480,000 after acquiring an additional 35,714 shares in the last quarter. 22.32% of the stock is currently owned by institutional investors and hedge funds.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.